Drugs whose prices have been reduced by the Medicare negotiation process established by the Inflation Reduction Act will not be subject to additional new discounts required in Part D as part of the law’s overhaul of the benefit design.
Under the negotiation process, older single-source drugs and biologics without generic or biosimilar competition will face minimum discounts of 25%,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?